Abstract:The transforming growth factor-beta (TGF-β) inhibits the growth of most epithelial and hematopoietic cells. The activity of the TGF-β-initiated signaling pathways is under tight control by processes including regulation of tumor suppressor SMAD proteins. TGF-β signaling is generally mediated through intracellular signal transducers and transcription factors called SMADs. Deregulation of TGF-β signaling contributes to pathogenesis of many diseases including cancer, fibrotic diseases, and vascular diseases. Loss of the TGF-β antiproliferative response is a hallmark in human cancer. However, genetic mutations in SMADs or TGF-β receptors are rare in immune system-derived cancers. Thus, the mechanisms underlying TGF-β resistance in lymphoma or leukemia are largely elusive. Objective: To elucidate the mechanisms underlying TGF-β resistance in B-cell lymphoma. Methods: Using protein array-based approach, we identified oncoproteins BCL6 as an interacting protein of tumor suppressor SMAD4. We further validated the BCL6-SMAD4 physical interaction by biochemical assays such as immunoprecipitation and in vitro binding assay. Transcriptional assays were used to assess the ability of BCL6 to repress the activity of SMAD4 as a transcription factor. DNA synthesis rate was assayed by 3H-thymidine incorporation in Burkitt-like lymphoma cell lines BL41, BJAB, Ramos, Daudi, and Raji. BCL6 expression was analyzed by Western blotting. BCL6 expression was knocked down in BJAB cells using siRNA. The binding of BCL6 to the TGF-β-responsive gene promoter was analyzed by chromatin immunoprecipitation. Results: The level of BCL6 was significantly higher in all B-cell lymphoma cell lines except BL41. These B-cell lymphoma cells with a high expression level of BCL6 were found to be refractory to TGF-β antiproliferative response, whereas BL41 cells underwent TGF-β-mediated growth inhibition. Knockdown of BCL6 could restore the TGF-β sensitivity in TGF-β resistant cells. Meanwhile, we have identified the oncoprotein BCL6 as a transcriptional corepressor of tumor suppressor SMAD4. BCL6 physically interacted with SMAD4, occupied the gene promoter of TGF-β target genes, disrupted the SMAD4-p300 interaction. Consequently, BCL6 repressed the transcriptional activity of SMAD4 and blocked the expression TGF-β-induced anti-proliferation factors. Conclusion: Our study provides compelling evidence that overexpression of BCL6, that often occurs in B-cell lymphoma, contributes to TGF-β resistance. Thus, our finding should provide insights into the mechanism of TGF-β anti-cancer actions. Knowledge gained from these studies will be used to design novel therapeutic strategies for prevention and treatment of human cancer.

Bcl6 Suppresses Cardiac Fibroblast Activation and Function Via Directly Binding to Smad4

Bcl6 Represses Smad Signaling in Transforming Growth Factor-Beta Resistance

Paired box 6 inhibits cardiac fibroblast differentiation

Bcl6 knockdown aggravates hypoxia injury in cardiomyocytes via the P38 pathway

50. Oncogene BCL6 Antagonizes Tumor Suppressor SMAD4 to Cause TGF-β Resistance

Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling.

EphrinB2 Regulates Cardiac Fibrosis Through Modulating the Interaction of Stat3 and TGF-β/Smad3 Signaling

ITGBL1 mediates fibroblast–cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy

BCL6 Attenuates Proliferation and Oxidative Stress of Vascular Smooth Muscle Cells in Hypertension

BHLH Transcription Factor TCF21 Inhibits Myofibroblast Formation and Cardiac Fibrosis

Hypoxia-stimulated Cardiac Fibroblast Production of IL-6 Promotes Myocardial Fibrosis Via the TGF- Β 1 Signaling Pathway

Loss of BTK Ameliorates the Pathological Cardiac Fibrosis and Dysfunction.

Targeted Disruption of Smad4 in Cardiomyocytes Results in Cardiac Hypertrophy and Heart Failure

Sirtuin 6 inhibits myofibroblast differentiation via inactivating transforming growth factor-β1/Smad2 and nuclear factor-κB signaling pathways in human fetal lung fibroblasts.

SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy.

Sirtuin 6 Inhibits Myofibroblast Differentiation Via Inactivating Transforming Growth Factor-Beta 1/Smad2 And Nuclear Factor-Kappa B Signaling Pathways In Human Fetal Lung Fibroblasts

Abstract 15700: ALK1-Mediated Smad1 Activation in a Myofibroblast Subset Protects the Infarcted Heart From Adverse Remodeling and Excessive Fibrosis

Downregulation of B4GALT5 attenuates cardiac fibrosis through Lumican and Akt/GSK-3β/β-catenin pathway

Abstract 13694: Hsf1 Attenuates Pressure Overload Induced-cardiac Fibrosis via Inhibiting Smad3 Phosphorylation and Nuclear Translocation

Downregulation of B4GALT5 Attenuates Cardiac Fibrosis Through Lumican and Akt/GSK-313/13-catenin Pathway

TSC-22 Promotes Transforming Growth Factor Β-Mediated Cardiac Myofibroblast Differentiation by Antagonizing Smad7 Activity